Compare Credo Technology Group Holding Ltd (CRDO) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Credo Technology Group Holding Ltd trades at $217.45 (market cap $41.35B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Credo Technology Group Holding Ltd is far larger — about 24.2× Nuvation Bio Inc. Class A Common Stock's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| CRDO | NUVB | |
|---|---|---|
Market Cap | $41.35B | $1.71B |
Volume | 7,290,508 | 5,448,712 |
Sector | Technology | Health |
52-Week High | $302.52 | $9.54 |
52-Week Low | $87.81 | $3.41 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $40.61B | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum indicated by bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth in Q2 2026 and a 33.83% net income margin. Recent news highlights Credo's positioning as a key beneficiary of AI infrastructure spending, with triple-digit revenue growth driven by high-speed connectivity solutions for data centers.
Outlook remains positive with 87.5% analyst buy ratings and a $267.33 consensus price target representing 21.5% upside. Key risks include premium valuation multiples (P/E 77.47) and customer concentration, while growth catalysts center on AI-driven demand and expanding optical product offerings. The stock's recent 20.3% monthly decline may present a buying opportunity given strong fundamentals.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
